Merck completes acquisition of Modifi Biosciences, Inc. to advance DNA modification enabled cancer therapeutics
Acquiring Company
Merck
Acquired Company
Modifi Bio
RahwayNew HavenManufacturingBiotechnologyHealthcareHealth CareBiotechnologyHealth CareDescription
Modifi Biosciences, a leader in the development of direct DNA modification enabled cancer therapeutics, has been acquired by Merck. This acquisition will enable Merck to leverage Modifi Biosciences' innovative approach to develop breakthrough therapies for some of the most refractory cancer types. The $30 million upfront acquisition, along with potential milestone payments totaling up to $1.3 billion, reflects the recognition of the potential of Modifi Biosciences' science by Merck.
Quick answer
Merck is acquiring Modifi Bio, announced October 23, 2024. Merck is based in Rahway, New Jersey, United States.
- How much did Merck pay for Modifi Bio?
- The deal value was not disclosed.
- What does Merck do?
- For over 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our..
- Where are Merck and Modifi Bio based?
- Merck is based in Rahway, New Jersey, United States. Modifi Bio is based in New Haven, Connecticut, United States.
- Who are the decision-makers at Merck?
- Fundz holds 3 contacts at Merck. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Healthcare and Manufacturing
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Boston Scientific completes acquisition of Axonics, Inc. to expand into sacral neuromodulation (November 15, 2024)
- Merck completes acquisition of investigational B-Cell depletion therapy, CN201, from Curon Biopharmaceutical (October 1, 2024)
- H.B. Fuller Company signs agreements to acquire Medifill Ltd. and GEM S.r.l. to expand its Medical Adhesive Technologies business (December 2, 2024)
- Gemini Bioproducts, LLC Acquires Selected Fetal Bovine Serum (FBS) Product Rights and Inventory from Bio-Techne (November 25, 2024)
- Medtronic completes acquisition of Fortimedix to enhance its surgical technology portfolio (November 22, 2024)
- AbbVie announces acquisition of Aliada Therapeutics, focusing on Alzheimer's disease and neuroscience pipeline (October 28, 2024)
Who to call at Merck, and when
When Merck changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Merck raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Merck, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Merck. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Merck makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Modifi Bio?
Modifi Bio was acquired by Merck, based in Rahway. The deal was reported on October 30, 2024. Merck is publicly traded (MRK) and operates in Manufacturing.
When did Merck acquire Modifi Bio?
Merck's acquisition of Modifi Bio was reported on October 30, 2024. Modifi Biosciences, a leader in the development of direct DNA modification enabled cancer therapeutics, has been acquired by Merck. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Modifi Bio do?
At Modifi Bio, we are changing the oncology treatment paradigm. Bypassing the conventional approach of indirectly targeting proteins in cancer cells, Modifi Bio is redefining the rules of oncology treatment: eradicating cancer via direct DNA modification. It is privately held, operating in Biotechnology, and is based in New Haven.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.